Crestone, Inc. ("Crestone") today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...

A newly developed antibiotic called EVG7 could offer a powerful new way to stop Clostridioides difficile, a dangerous gut bacterium that often returns after treatment. In mouse studies, researchers ...

About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual ...

Acurx Pharmaceuticals, Inc.  ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced ...

Dear Dr. Roach: About one year ago, I had Clostridioides difficile (C. diff) that was treated with 125 mg of vancomycin for about four weeks. I had none of the usual risk factors, and the cause was ...

Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...

Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary ...

莱顿的科学家们开发出一种名为EVG7的新型抗生素，仅需极小剂量即可对抗危险的肠道细菌——艰难梭菌（Clostridioides difficile, C. difficile）。 这种疗法似乎还能大大降低感染复发的可能性，而复发是目前抗生素治疗中常见的问题。相关研究结果已发表在《自然·通讯》（Nature Communications）杂志上。

Mikrobiomik has become the first organisation in Spain to receive authorisation to prepare and process faecal microbiota for treating Clostridioides difficile infection, following approval of its oral ...